Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alternative Dosing Schedules of Azacitidine: A Real-World Study Across South American Centers.
Castelo L, da Silva WF, Lincango M, Buccheri V, Perusini A, Arbelbide J, Iastrebner M, Gonzalez J, Pereyra P, Pereira TDM, Marchi LL, Rocha V, Belli CB, Velloso EDRP. Castelo L, et al. Among authors: buccheri v. Clin Lymphoma Myeloma Leuk. 2024 Feb 14:S2152-2650(24)00062-4. doi: 10.1016/j.clml.2024.02.003. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38462425 No abstract available.
Ezrin is highly expressed and a druggable target in chronic lymphocytic leukemia.
Lipreri da Silva JC, Saldanha-Araujo F, de Melo RCB, Vicari HP, Silva-Carvalho AE, Rego EM, Buccheri V, Machado-Neto JA. Lipreri da Silva JC, et al. Among authors: buccheri v. Life Sci. 2022 Dec 15;311(Pt B):121146. doi: 10.1016/j.lfs.2022.121146. Epub 2022 Nov 3. Life Sci. 2022. PMID: 36336127 Free article.
Treatment outcomes in classic Hodgkin lymphoma: 5-year update from the Brazilian Hodgkin Lymphoma Registry.
Biasoli I, Castro N, Colaço Villarim C, Traina F, Chiattone CS, Praxedes M, Solza C, Perobelli L, Baiocchi O, Gaiolla R, Boquimpani C, Buccheri V, Bonamin Sola C, de Oliveira de Paula E Silva R, Ribas AC, Steffenello G, Pagnano K, Soares A, de Souza C, Spector N. Biasoli I, et al. Among authors: buccheri v. EJHaem. 2023 Oct 4;4(4):1191-1195. doi: 10.1002/jha2.804. eCollection 2023 Nov. EJHaem. 2023. PMID: 38024602 Free PMC article. No abstract available.
Treatment patterns and outcomes for Hodgkin Lymphoma patients aged 60 and older: a report from the Brazilian Prospective Hodgkin Lymphoma Registry.
Goveia L, Castro N, de Souza C, Colaço Villarim C, Traina F, Chiattone CS, Praxedes M, Solza C, Perobelli L, Baiocchi O, Gaiolla R, Boquimpani C, Buccheri V, Bonamin Sola C, de Oliveira Paula E Silva R, Ribas AC, Steffenello G, Pagnano K, Soares A, Souza Medina S, Silveira T, Zattar Cecyn K, Carvalho Palma L, de Oliveira Marques M, Spector N, Biasoli I. Goveia L, et al. Among authors: buccheri v. Ann Hematol. 2023 Oct;102(10):2815-2822. doi: 10.1007/s00277-023-05352-w. Epub 2023 Jul 21. Ann Hematol. 2023. PMID: 37474632
Consolidative mediastinal radiotherapy for advanced-stage classical Hodgkin lymphoma with bulky disease in patients who achieve complete response after chemotherapy in PET-CT era.
Atanazio MJ, Santos FM, Duran A, Maia ACA, Alves LB, Velasques RD, Rocha V, Buccheri V. Atanazio MJ, et al. Among authors: buccheri v. Rep Pract Oncol Radiother. 2022 Oct 31;27(5):856-862. doi: 10.5603/RPOR.a2022.0092. eCollection 2022. Rep Pract Oncol Radiother. 2022. PMID: 36523799 Free PMC article.
Structural and functional basis of mammalian microRNA biogenesis by Dicer.
Zapletal D, Taborska E, Pasulka J, Malik R, Kubicek K, Zanova M, Much C, Sebesta M, Buccheri V, Horvat F, Jenickova I, Prochazkova M, Prochazka J, Pinkas M, Novacek J, Joseph DF, Sedlacek R, Bernecky C, O'Carroll D, Stefl R, Svoboda P. Zapletal D, et al. Among authors: buccheri v. Mol Cell. 2022 Nov 3;82(21):4064-4079.e13. doi: 10.1016/j.molcel.2022.10.010. Mol Cell. 2022. PMID: 36332606 Free PMC article.
Lower access to risk stratification tests and drugs, and worse survival of chronic lymphocytic leukaemia patients treated in public as compared to private hospitals in Brazil: A retrospective analysis of the Brazilian registry of chronic lymphocytic leukaemia.
Pfister V, Marques FM, Parra F, Yamamoto M, Gonçalves MV, Perobelli L, Buccheri V, Bandeira R, Fortier S, Azevedo A, Santucci R, Bellesso M, Fogliatto L, Ribeiro G, Lopes GS, Ikoma M, Figueiredo VP, Metze IGHL, Chiattone CS, Arrais-Rodrigues C. Pfister V, et al. Among authors: buccheri v. EJHaem. 2022 May 6;3(3):698-706. doi: 10.1002/jha2.444. eCollection 2022 Aug. EJHaem. 2022. PMID: 36051063 Free PMC article.
Prediction of disability-free survival in healthy older people.
Neumann JT, Thao LTP, Murray AM, Callander E, Carr PR, Nelson MR, Wolfe R, Woods RL, Reid CM, Shah RC, Newman AB, Williamson JD, Tonkin AM, McNeil JJ; ASPREE investigators. Neumann JT, et al. Geroscience. 2022 Jun;44(3):1641-1655. doi: 10.1007/s11357-022-00547-x. Epub 2022 Apr 14. Geroscience. 2022. PMID: 35420334 Free PMC article. Clinical Trial.
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.
Zinzani PL, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, de Oliveira JSR, Buccheri V, Perini GF, Dickinson M, McDonald A, Özcan M, Sekiguchi N, Zhu Y, Raut M, Saretsky TL, Nahar A, Kuruvilla J. Zinzani PL, et al. Among authors: buccheri v. Blood Adv. 2022 Jan 25;6(2):590-599. doi: 10.1182/bloodadvances.2021004970. Blood Adv. 2022. PMID: 34644372 Free PMC article.
61 results